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Why proper understanding of confidence 
intervals and statistical significance is important
Guidelines for reporting results from randomised trials have long underscored the importance of confidence intervals.1 Confidence intervals 
are informative as they show the likely range of 
effect sizes supported by the findings, whereas P 
values dichotomise the findings based on statistical 
significance at an arbitrary cut-off.2 Reviews of 
contemporary trials show that researchers mostly 
adhere to this advice.3 Despite this, misinterpretation 
stubbornly persists.4 First, many trials are interpreting 
absence of evidence as evidence of no effect, concluding 
an intervention is ineffective when in fact the results 
suggest its effectiveness is uncertain. Second, in some 
trials it might be correct to conclude that a treatment 
is effective (or harmful), despite the non-statistically 
significant result; yet researchers persist in unhelpful 
language such as “not statistically significant”.
Thus, while researchers are abiding by reporting 
guidelines and including confidence intervals, 
these are rarely fully interpreted in the conclusions 
(ie, researchers are not abiding by the philosophy 
underpinning the reason for the guidelines). It is this 
paradox that led to recent campaigns demanding 
appropriate interpretation of confidence intervals.5,6 
Despite availability of publications addressing the 
statistical philosophy underpinning hypothesis testing, 
there is a dearth of practical guidelines for investigators, 
reviewers and editors in correct interpretation of 
findings from randomised controlled trials.
Here we provide a practical guide, bridging the gap 
between statistical philosophy and the desire to 
draw conclusive findings from most trials (Box 1). 
To this end, we provide recommendations for the 
interpretation of the primary outcome result, where we 
urge interpretation of the full range of the confidence 
interval and its overlap with effect sizes considered to 
be clinically important. While we advocate for a more 
holistic interpretation considering contextual factors, 
we urge transparency in these arguments. We illustrate 
these recommendations using two topical case studies 
(online Supporting Information).7,8 The first study 
aimed to determine whether the efficacy of the N95 
respirator in controlled settings could be maintained in 
real life, where compliance may be suboptimal. The trial 
reported a non-significant finding which it interpreted 
as “no significant difference”.7 The second study 
investigated whether lopinavir–ritonavir provides any 
treatment benefit in patients with severe coronavirus 
disease 2019, reporting non-significant findings which it 
interpreted as “no difference” or “no benefit”.8
Practical guide
Interpreting a confidence interval
The imperfect nature of any approach to hypothesis 
testing is now widely recognised.2 One approach, 
advocated by Neyman–Pearson, uses an objective 
but arbitrary cut-point (usually a P value of 0.05) for 
statistical significance. On the other hand, Fisher 
argued for an approach based on a continuum with 
no set threshold, also arguing for the consideration of 
other contextual factors. However, neither approach 
acknowledges the importance of the size of any 
treatment effect. Focus therefore shifted to the 
reporting of confidence intervals.9 The confidence 
interval can be interpreted as providing a range of 
treatment effects supported by the study. Not all values 
within the interval are equally supported: those closer 
to the point estimate have more support, and support 
tapers the closer to the bounds of the interval.
When interpreting confidence intervals in relation 
to clinically important effect sizes (see below), 
primary outcome results can be directive despite 
not being statistically significant. This can arise 
when the confidence interval excludes a clinically 
meaningful benefit (or harm) (Box 2, row 2). Directive, 
yet not statistically significant results, can also arise 
when the confidence interval mostly overlaps with 
values indicative of benefit (or harm), that is, when 
the interval covers treatment effects mostly in one 
direction (Box 2, rows 1 and 3). In reality, statistically 
non-significant results can also arise in situations 
where the confidence interval is wide and includes 
treatment effects that are both beneficial and harmful. 
Such results should be interpreted as inconclusive 
(Box 2, row 4). The primary outcome in the ResPECT 
trial7 (Supporting Information) is an example of a 












1 Recommendations for interpreting results from 
randomised controlled trials
The interpretation of the findings should be informative:
• Directive conclusions from randomised trials are desirable. 
Investigators should refrain from using unhelpful statements 
like “statistically not significant” in the overall conclusion of 
the trial findings.
Confidence intervals should be properly interpreted:
• Interpretation of the trial findings should consider the range of 
effects supported by the confidence intervals.
• Values at the tails of the confidence interval are less supported 
by the data from the trial.
Clinically important treatment effects must be considered:
• Only when the confidence interval conclusively rules out (ie, 
does not overlap with) any treatment effect considered to be 
clinically important can a directive conclusion of no effect be 
made.
• A confidence interval result that unequivocally includes both 
benefit and harm should be interpreted as inconclusive.
The overall conclusion should be justified:
• Overall conclusions should be contextualised. This con-
textualisation includes not only the primary outcome but 
also associated harms, costs, secondary outcomes or other 
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statistically non-significant primary outcome, but 
which probably rules out any meaningful benefit, 
whereas the outcome mortality in the lopinavir–
ritonavir trial8 (Supporting Information) is an example 
of a statistically non-significant result which is 
probably inconclusive.
Clinically important treatment effects
Confidence intervals need to be interpreted with 
an understanding of what are clinically important 
changes in outcomes — referred to as clinically 
important treatment effects. The notion of the 
minimum clinically important effect size (ie, the 
smallest effect size that is thought to be of any 
clinical importance) will be familiar to many 
researchers. Ideally, the sample size should be 
based on being adequately powered to detect this 
effect size.10 However, given the nature of research 
which is often constrained by limited budgets and 
resources, sample size calculations are often based 
on effect sizes that are thought to be achievable 
or that yield a feasible sample size.11 Second, the 
minimally clinically important difference in a 
superiority trial is related to the non-inferiority or 
equivalence margin considered in non-inferiority or 
equivalence trials.12 Minimum clinically important 
effect sizes thus inform what a clinically important 
effect is. Ideally, what constitutes a clinically 
important effect should be pre-specified, well 
justified and include opinions of both clinicians 
and patients.13 Moreover, it should not be taken as 
absolute and should be interpreted on a continuum. 
For trials that evaluate effects on outcomes such 
as mortality, any positive effect of the intervention 
(however small) might be clinically important. 
Reporting results on the absolute scale, perhaps as 
a number needed to treat, can aid in interpretation 
of clinical importance.14 No minimally important 
clinical differences were specified in either of the 
two studies considered here,7,8 but in both examples 
we use logical reasoning to consider what plausible 
smallest important differences might be (Supporting 
Information).
Importance of informative conclusions
In almost all situations, a technically correct conclusion 
of “statistically non-significant” is unhelpful. Those 
seeking information wish to know whether the findings 
are inconclusive (more research is required) or whether 
the trial can be directive in its conclusions. Both 
studies are statistically not significant for their primary 
outcomes; however, concluding that the study was 
“non-significant” in the study conclusions is unhelpful. 
Despite being statistically non-significant, the primary 
outcome result from the ResPECT trial suggests there is 
probably no benefit from the N95 respirator; moreover, 
the confidence interval also covers regions which might 
be considered as clinically important increases in risk. 
However, when considering the full range of treatment 
effects supported by the confidence intervals for both 
primary and secondary outcomes for the lopinavir–
ritonavir trial, we see that the results are compatible 
with both benefit and harm, and this result is therefore 
inconclusive.
Holistic interpretation
There are of course many considerations other than 
the primary outcome result. First and foremost, it is 
necessary to consider the robustness of the trial design, 
risks of bias, and generalisability. Both the ResPECT 
trial and the lopinavir–ritonavir trial appear to be 
free from any obvious bias. While the interpretation 
of the trial findings should focus on the result of 
the primary outcome, other contextual factors are 
important. These might include secondary outcomes, 
harms, costs, and evidence from other trials. This more 
holistic interpretation is endorsed by the CONSORT 
statement.9
In the case of N95 respirators, the community wishes 
to know whether N95 respirators, which are more 
expensive and uncomfortable to wear, provide any 
extra benefit over medical masks. Concluding any 
risk of harm from the N95 respirator mask appears 
counter-intuitive, but might be a reflection of risk 
compensation. Moreover, given this suggestion of 
increased risk appears only at the extreme tail of the 
2 Illustrative example of how to interpret a statistically non-significant confidence interval
MID = minimally (clinically) important difference. This illustration considers a continuous outcome for which changes in the region of 5 
points are considered to be probably unimportant. The MID is therefore around 5. The exact position of the point estimate has no relevance 

















confidence interval, it might reflect random chance. 
If the N95 respirator is truly compatible with harm, 
the secondary outcomes would likely have shown 
that signal too. In fact, all of the secondary outcomes 
seemed to indicate either no effect or a likely protective 
effect. Thus, a reasonable interpretation based on the 
primary outcomes is that N95 respirators probably 
provide no added protection. The primary outcome 
result for the lopinavir–ritonavir trial is uncertain; 
other outcomes were also mostly uncertain. Evidence 
from other trials was rapidly evolving, but none 
pointed convincingly to any suggestion that lopinavir–
ritonavir could be abandoned as an ineffective 
treatment, at least not just yet.
Summary
Evidence-based medicine requires careful execution 
of randomised trials of high internal validity and 
high generalisability. A growing body of literature 
on the conduct and reporting of randomised trials 
warns against such things as manipulation of 
outcome selection and multiplicity of analyses, and 
provides guidelines on good practice, such as pre-trial 
registration. Increasingly, investigators are adhering 
to this advice. However, investigators, reviewers and 
editors are still failing to correctly interpret statistically 
non-significant results. Clinical interpretation of trial 
results needs to shift to being centred on whether 
the results (ie, values supported by the confidence 
intervals) are consistent with a clinically important 
effect.
Pre-specification and justification of clinically 
important effect sizes should become the norm. 
Minimally important effect sizes have been a feature of 
sample size calculations, especially in non-inferiority 
trials, but they are fundamental for the interpretation 
of all randomised trials. Although there is as yet no 
consensus on how to determine these values, it does 
not mean this issue can be ignored. Reporting on 
absolute scales is almost certainly helpful here.
The interpretation of the primary outcome result 
is not the only consideration when determining 
the final conclusions. There may, for example, be 
side effects from treatments, cost considerations 
or issues of overtreatment or invasiveness and 
secondary supportive outcomes. These other 
considerations might lend support to an overall 
conclusion that the treatment is unlikely to be 
beneficial, despite a non-significant finding. 
However, it is crucial that there is transparency in 
how this conclusion is reached.
Clear and conclusive findings are more appealing to 
journal editors and to their readership. Sometimes, but 
not always, trials which are statistically not significant 
can still be directive. Unfortunately, many trials 
ultimately end up being uncertain simply because  
they are too small. Trials undoubtedly need larger 
sample sizes to reduce uncertainty and to ensure 
they are powered to detect clinically important effect 
sizes.15
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